Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-02-27 | Reverse | 1:30 |
| 2023-11-30 | Reverse | 1:4 |
Incannex Healthcare Limited develops and sells pharmaceutical-grade cannabinoid products in Australia, including clinical-stage treatments for sleep apnea, brain injury, and inflammatory conditions, through partnerships with hospitals and research...
IHL-42X, Incannex's lead investigational oral drug combining dronabinol and acetazolamide for obstructive sleep apnea, is in Phase 2/3 trials with FDA Fast Track designation.
On July 30, 2025, Incannex Healthcare announced positive topline results from its RePOSA Phase 2 clinical trial for IHL-42X, a novel oral drug candidate for obstructive sleep apnea (OSA). The trial demonstrated statistically and clinically significant improvements, with the drug reducing the Apnoea-Hypnoea Index (AHI) by up to 83% from baseline, leading to a dramatic and volatile increase in the company's stock price and trading volume.
In a decisive move to strengthen its financial structure and enhance shareholder value, Incannex Healthcare executed a multi-faceted capital management strategy in 2025. The company utilized its at-the-market (ATM) facility to fund the cancellation of all outstanding Series A Warrants, removing a significant potential for share dilution, and subsequently authorized a $20 million share repurchase program.
Dallas, Texas--(Newsfile Corp. - October 1, 2026) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). IXHL's FY26 update moves the IHL-42X story from DReAMzz preparation into active clinical execution, with first-patient dosing underway and the balance sheet providing runway for at least 12 months of planned operations.
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
 IRD | $4.38 | COMPARE |
 TTRX | $11.63 | COMPARE |
 AGEN | $7.56 | COMPARE |
 LUCD | $0.63 | COMPARE |
 SEER | $2.19 | COMPARE |
 CGTX | $0.91 | COMPARE |
 ZYBT | $1.16 | COMPARE |
 SCLX | $3.01 | COMPARE |
